The RATinG (Risk Adapted Therapy in Acute GvHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for the early treatment of participants with high-risk...
Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon previously...
Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.
CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab and with current standard of care, azacitidineSix...
Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of 3.08% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 46.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 22.22% and 9.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...
Vertex (VRTX) delivered earnings and revenue surprises of 8.67% and 4.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Humanigen, Inc. (“Humanigen” or “the Company”) (NASDAQ: HGEN) and...
/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Humanigen, Inc. (NASDAQ: HGEN) alleging...